TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding TScan Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 27 | 1 | 29 | +3 |
| Shares | 10.1M | 1.25M | 9.86M | +972.5K (+10.9%) |
| Value | $83.5M | $9.35M | $44.4M | −$29.8M (−40.1%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deer Management Co. LLC | 1,245,505 | $5.61M | 0.14% |
| Woodline Partners LP | 99,900 | $450.0K | 0.01% |
| Nan Fung Group Holdings Ltd | 48,600 | $219.0K | 0.06% |
| Bridgeway Capital Management, LLC | 40,000 | $180.0K | 0.00% |
| Marquette Asset Management, LLC | 21,618 | $97.0K | 0.02% |
| HRT Financial LP | 20,829 | $93.0K | 0.00% |
| LPL Financial LLC | 13,000 | $59.0K | 0.00% |
| Jane Street Group, LLC | 11,307 | $51.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,770 | $17.0K | 0.00% |
| Bank of America Corp | 189 | $1.00K | 0.00% |
Sold out (7)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Wellington Management Group LLP | 139,566 | $1.16M |
| Monashee Investment Management LLC | 100,000 | $834.0K |
| Two Sigma Investments, LP | 22,817 | $190.0K |
| Schonfeld Strategic Advisors LLC | 22,200 | $185.0K |
| Two Sigma Advisers, LP | 13,000 | $108.0K |
| Citadel Advisors LLC | 11,922 | $99.0K |
| Goldman Sachs Group Inc | 11,531 | $96.0K |
Not filed for Q4 2021 yet (1)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Deer IX & Co. Ltd. | 1,245,505 | $9.35M |